TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients DMS Hossain, SK Pal, D Moreira, P Duttagupta, Q Zhang, H Won, J Jones, ... Clinical Cancer Research 21 (16), 3771-3782, 2015 | 200 | 2015 |
Cell death‐associated molecular‐pattern molecules: inflammatory signaling and control B Sangiuliano, NM Pérez, DF Moreira, JE Belizário Mediators of inflammation 2014 (1), 821043, 2014 | 163 | 2014 |
Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo YL Su, X Wang, M Mann, TP Adamus, D Wang, DF Moreira, Z Zhang, ... Blood, The Journal of the American Society of Hematology 135 (3), 167-180, 2020 | 123 | 2020 |
Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity DMS Hossain, C Dos Santos, Q Zhang, A Kozlowska, H Liu, C Gao, ... Blood, The Journal of the American Society of Hematology 123 (1), 15-25, 2014 | 115 | 2014 |
Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. KM Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, Buettner R ... Blood 127 (13), 1687-700, 2016 | 100* | 2016 |
The esc-eorp euro-endo (european infective endocarditis) registry G Habib, P Lancellotti, PA Erba, A Sadeghpour, M Meshaal, A Sambola, ... European Heart Journal-Quality of Care and Clinical Outcomes 5 (3), 202-207, 2019 | 87 | 2019 |
STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers D Moreira, T Adamus, X Zhao, YL Su, Z Zhang, SV White, P Swiderski, ... Clinical Cancer Research 24 (23), 5948-5962, 2018 | 87 | 2018 |
Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry G Boriani, M Proietti, C Laroche, L Fauchier, F Marin, M Nabauer, ... EP Europace 21 (7), 1013-1022, 2019 | 74 | 2019 |
Intracellular processing of immunostimulatory CpG–siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape S Nechaev, C Gao, D Moreira, P Swiderski, A Jozwiak, CM Kowolik, ... Journal of Controlled Release 170 (3), 307-315, 2013 | 68 | 2013 |
Myeloid cell–targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell–mediated immunity D Moreira, S Sampath, H Won, SV White, YL Su, M Alcantara, C Wang, ... The Journal of clinical investigation 131 (2), 2021 | 66 | 2021 |
TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells D Moreira, Q Zhang, DMS Hossain, S Nechaev, H Li, CM Kowolik, ... Oncotarget 6 (19), 17302, 2015 | 66 | 2015 |
Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities M Kortylewski, D Moreira Cancer Immunology, Immunotherapy 66, 979-988, 2017 | 59 | 2017 |
TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. KM Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, Diamond D, Yuan ... J Leukocyte Biology, 2017 | 56 | 2017 |
Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and/or enzalutamide therapy SK Pal, D Moreira, H Won, SW White, P Duttagupta, M Lucia, J Jones, ... International Journal of Molecular Sciences 20 (8), 1831, 2019 | 54 | 2019 |
Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs KPC Araujo, G Bonuccelli, CN Duarte, TP Gaiad, DF Moreira, D Feder, ... PLoS One 8 (4), e61367, 2013 | 53 | 2013 |
Using pharmacogenomic databases for discovering patient-target genes and small molecule candidates to cancer therapy JE Belizário, BA Sangiuliano, M Perez-Sosa, JM Neyra, DF Moreira Frontiers in pharmacology 7, 312, 2016 | 37 | 2016 |
Role of SOCS-1 gene on melanoma cell growth and tumor development JAB Scutti, AL Matsuo, FV Pereira, MH Massaoka, CR Figueiredo, ... Translational oncology 4 (2), 101-109, 2011 | 36 | 2011 |
B cell lymphoma immunotherapy using TLR9-targeted oligonucleotide STAT3 inhibitors X Zhao, Z Zhang, D Moreira, YL Su, H Won, T Adamus, Z Dong, Y Liang, ... Molecular Therapy 26 (3), 695-707, 2018 | 35 | 2018 |
Differential antitumor effects of IgG and IgM monoclonal antibodies and their synthetic complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells AS Dobroff, EG Rodrigues, MA Juliano, DM Friaça, ES Nakayasu, ... Translational Oncology 3 (4), 204-217, 2010 | 35 | 2010 |
Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling BMC Cancer 15 (70), 2015 | 34 | 2015 |